Haemophilia Treatment Market to Grow with a CAGR of 5.73% through 2028
Increasing prevalence of hemophilia and surging trend of prophylaxis
treatment is expected to drive the Global Haemophilia Treatment Market growth
in the forecast period, 2024-2028.
According to TechSci Research report, “Haemophilia Treatment Market –
Global Industry Size, Share, Trends, Competition Forecast &
Opportunities, 2028”, the Global Haemophilia Treatment Market stood at USD 11.34
billion in 2022 and is anticipated to grow with a CAGR of 5.73% in the forecast
period, 2024-2028. The increase in research and development studies focused on
treatment therapies, along with the growing target population and diagnosis
rate, are key factors driving the growth of the hemophilia treatment market.
Additionally, the rise in the use of prophylactic treatment for
hemophilia contributes to this growth. However, the high cost of hemophilia
treatment, limited availability of medicines, and serious adverse effects
associated with plasma-derived products are anticipated to hinder market
growth. On the other hand, the growing awareness about hemophilia in developing
countries presents an opportunity for the expansion of the hemophilia treatment
market.
Browse over XX market data Figures spread through XX Pages and an
in-depth TOC on
"Global Haemophilia Treatment Market.”
The growing global initiatives by government and non-government
organizations to raise awareness about hemophilia drugs are key factors driving
the market growth. The increasing adoption of prophylactic treatment is also
expected to contribute to the demand for hemophilia. Treatment involves regular
replacement of clotting factors, and alternative therapies without clotting
factors are also being utilized.
The haemophilia market is experiencing growth due to factors such as
increased healthcare expenditure, preference for prophylactic treatment, higher
diagnosis rates, and significant usage of recombinant coagulation factor. In
the near future, recombinant coagulation factor concentrates are projected to
dominate the global haemophilia market. Physicians prefer recombinant
coagulation factor, which is anticipated to drive the haemophilia market in the
forecast period due to its lower risk of bloodborne infection. On the other
hand, plasma-derived coagulation factor is expected to have a slower CAGR
during the forecast period due to a higher risk of blood-associated infections
and limited availability of plasma derived from blood.
The availability of limited treatment therapy options and the increasing
responsibility of regulatory authorities to address treatment have led to
increased research and development efforts. Both public and commercial
healthcare organizations are investing significantly in specialized clinics to
meet the specific demands of patients. The number of Hemophilia treatment
centers is increasing to provide treatment to underprivileged individuals.
Authorities emphasize that individuals with Hemophilia receive treatment at
specialized facilities for optimal care and health education. The construction
of healthcare centers is expected to fuel the growth of the Hemophilia Market.
One of the primary drivers of haemophilia market growth is the
increasing prevalence of haemophilia, which is driving the demand for treatment
options. Patients with severe haemophilia require frequent treatment to
maintain sufficient clotting factors and prevent bleeding. According to the
Centers for Disease Control and Prevention, Hemophilia A affects 1 in every
5,000 male births in the United States. As the number of dependent patients
requiring comprehensive care continues to rise, this significant prevalence is
expected to have a substantial impact on the market. Moreover, patients
receiving quality care are more likely to have fewer co-morbidities and a
reduced risk of severe bleeding. Thus, the increasing number of patients with
haemophilia has led to a higher demand for haemophilia therapy, resulting in
increased product adoption rates.
The Global Haemophilia Treatment Market is segmented into type, product,
treatment, therapy, regional distribution, and company.
Based on type, Hemophilia A is projected to maintain a significant
market share throughout the forecast period. It is the most prevalent severe
bleeding disorder. Replacement therapy, which involves providing the missing
coagulation factor, has been the primary treatment approach for both
prophylaxis and bleeding management.
According to the data published by the World Federation of Hemophilia in
2021, hemophilia A primarily affects males, accounting for 146,246 cases (88%),
followed by females with 5,636 cases (3%), and cases where the sex is unknown,
totaling 9,917 (6%). The primary medication used for treating hemophilia A is a
concentrated FVIII product, also known as clotting factor. Advances in
recombinant protein engineering, gene therapy, and novel strategies targeting
the coagulation cascade have enabled the development of recombinant factor
products in the laboratory, reducing reliance on human-derived pools of
donor-sourced plasma. For example, in December 2021, Pfizer Inc. and Sangamo
Therapeutics, Inc., a genomic medicines company, released updated follow-up
data from the Phase 1/2 Alta study of giroctocogene fitelparvovec, an
investigational gene therapy for patients with moderately severe to severe
hemophilia A. The increasing focus on gene therapies for Hemophilia A is
expected to drive the growth of this segment.
Based on region, North America segment is expected to grow during the
forecast period. Among all regions, North America dominates the market
with the largest market share during the forecast period. The initial drivers
of regional development include the increasing prevalence and propensity for
preventative medicine. In the United States, this condition is often diagnosed
early in life. The growth of the hemophilia market in the region is driven by
therapeutic advances in hemophilia, leading to the approval of new agents by
the Food and Drug Administration, increasing awareness of technologically
advanced products, rising prevalence of hemophilia, and a large patient pool.
The United States is the largest market in the region, with
approximately 14,816 patients with hemophilia in 2020 (11,790 with Hemophilia A
and 3,026 with Hemophilia B). In Canada, there were 3,924 patients with
hemophilia in 2020 (3,223 with Hemophilia A and 701 with Hemophilia B). The
high number of hemophilia cases in these regions is expected to drive market
growth due to the higher adoption of hemophilia therapies. Furthermore, a
November 2021 news report in the United States highlighted the potential of
gene therapy to reduce or even eliminate life-threatening bleeding episodes in
individuals with hemophilia. The use of adeno-associated viral (AAV)
vector-based gene therapy aims to help patients with hemophilia A express FVIII
in their livers. Phase 1/2 clinical studies have shown promising results in the
majority of patients. The increasing research on gene therapies and favorable
outcomes are expected to drive market growth in the United States. On the other
hand, Asia-Pacific is expected to experience significant growth during the
forecast period. Factors such as increased per capita use of medications for
factor VIII and IX deficiencies and early disease detection in countries like
Japan, India, Indonesia, and Malaysia contribute to this growth.
Major companies operating in Global Haemophilia Treatment Market
are:
- Bayer AG
- BioMarin
Pharmaceutical, Inc.
- CSL
Behring LLC
- Kedrion
S.p.A
- Novo
Nordisk A/S
- Pfizer,
Inc.
- Octapharma
AG
- Sanofi
S.A.
- Takeda
Pharmaceutical Company
- Grifols
SA
Download Free Sample Report
Customers can also request for 10% free customization on this report.
“The growing number of hemophilic patients and the increasing prevalence
of genetic abnormalities worldwide are key factors that positively impact the
market. Moreover, the rising diagnosis rate of the disease and the growing
adoption of prophylactic treatment for hemophilia present profitable growth
opportunities for leading market players. Furthermore, government agencies in
various countries are organizing extensive awareness campaigns to promote early
diagnosis and appropriate screening procedures for neonates, thereby creating a
positive market outlook. Additionally, substantial investments in research and
development (R&D) activities are being made due to the limited availability
of treatment options. Notably, industry leaders are focused on introducing
advanced diagnostic tools and therapies to enhance the effectiveness and
precision of hemophilia treatment, further contributing to a favorable market
landscape. Additionally, significant investments are being made to expand the
establishment of specialized hemophilia treatment centers (HTCs) globally,
which is expected to drive market growth.,” said Mr. Karan Chechi, Research
Director with TechSci Research, a research-based management consulting firm.
“Haemophilia Treatment Market Segmented By Type (Haemophilia A, Haemophilia B,
Haemophilia C), By Product (Recombinant Coagulation Factor Concentrates, Plasma
Derived Coagulation Factor Concentrate, Desmopressin, Antifibrinolytics Agents), By Treatment (On-demand and Prophylaxis), By Therapy (Replacement Therapy, ITI
therapy and Gene Therapy), By Region and Competition, Forecast & Opportunities, 2018-2028F”, has evaluated the future growth potential
of Global Haemophilia Treatment Market and provides statistics &
information on market size, structure and future market growth. The report
intends to provide cutting-edge market intelligence and help decision makers
take sound investment decisions. Besides, the report also identifies and
analyzes the emerging trends along with essential drivers, challenges, and
opportunities in Global Haemophilia Treatment Market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]
Website: https://www.techsciresearch.com